Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | RARB | P10826 | 3/20 | 0.32 |
| ▸ | RARA | P10276 | 2/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | RARG | P13631 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.31 |
| ▸ | RXRG | P48443 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18315032 | 1.00 | KIF11 (0.36) | KIF11S1PR1RARBRARACYP11B1 | |
| SCHEMBL18314844 | 0.95 | KIF11 (0.33) | KIF11S1PR1RARBRARACYP11B1 | |
| SCHEMBL18314848 | 0.93 | KIF11 (0.35) | KIF11S1PR1RARB | |
| SCHEMBL18315024 | 0.91 | KIF11 (0.40) | KIF11S1PR1RARBRARACYP11B1 | |
| SCHEMBL18315056 | 0.91 | GRM2 (0.32) | S1PR1 | |
| SCHEMBL18315052 | 0.89 | S1PR1 (0.34) | S1PR1RARBRARARARG | |
| SCHEMBL18314993 | 0.89 | S1PR1 (0.33) | S1PR1FFAR1PPARD | |
| SCHEMBL18314816 | 0.89 | S1PR1 (0.33) | S1PR1FFAR1PPARD | |
| SCHEMBL18314926 | 0.89 | RARB (0.39) | KIF11S1PR1RARBRARARARG | |
| SCHEMBL18314911 | 0.89 | RARB (0.39) | KIF11S1PR1RARBRARARARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160362605-A1 | LIQUID CRYSTAL COMPOUND HAVING 1,1,3,3-TETRAFLUOROALLYLOXY GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2016-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362605-A1 | LIQUID CRYSTAL COMPOUND HAVING 1,1,3,3-TETRAFLUOROALLYLOXY GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | TCOF1, PIEZO1, RCC1 | KIF11 912/4885S1PR1 3198/4885RARB 2668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.